API | zosuquidar

zosuquidar Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Zosuquidar is an experimental antineoplastic drug. Zosquidir inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are trans-membrane proteins that pump foreign substances out of cells in an ATP dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents. ^Wikipedia

Chemistry

SMILES: O[C@@H](COc1cccc2ncccc12)CN1CCN([C@@H]2c3ccccc3[C@@H]3[C@H](c4ccccc42)C3(F)F)CC1
InChIKey: IHOVFYSQUDPMCN-DBEBIPAYSA-N
Mol. Mass: 527.62
ALogP: 5.21 Partition coefficient
ChEMBL Molecule:
zosuquidar

More Chemistry

Pharmacology

Mechanisms of Action:
- Phosphatidylcholine translocator ABCB4 (Homo sapiens) ^UniProt
- Multidrug resistance protein 1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

zosuquidar

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue